General
Preferred name
TOLAZAMIDE
Synonyms
U-17835 ()
NSC-70762 ()
Tolinase ()
P&D ID
PD001453
CAS
1156-19-0
Tags
natural product
drug
available
Approved by
FDA
First approval
1966
Drug Status
investigational
approved
Drug indication
Diabetic complication
Antidiabetic
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION A sulfonylurea family drug inhibiting sulfonylurea receptor 1 (ABCC8)/Kir6.2 (KCNJ11) potassium channel activity. (GtoPdb)
DESCRIPTION Oral hypoglycemic agent; stimulates pancreatic islet cells to secrete insulin (LOPAC library)
DESCRIPTION Tolazamide, a sulphonylurea derivative, could be a hypoglycemic agent which is commonly used in Type 2 diabetes. (BOC Sciences Bioactive Compounds)
Compound Sets
23
AdooQ Bioactive Compound Library
A18140
BOC Sciences Bioactive Compounds
tolazamide-cas-1156-19-0-item-55083
Cayman Chemical Bioactives
23545
ChEMBL Approved Drugs
CHEMBL817
ChEMBL Drugs
CHEMBL817
Drug Repurposing Hub
DrugBank
DB00839
DrugBank Approved Drugs
DB00839
DrugCentral
2694
DrugCentral Approved Drugs
2694
DrugMAP
DMIHRNA
DrugMAP Approved Drugs
DMIHRNA
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
6847
LOPAC library
MedChem Express Bioactive Compound Library
HY-B0920
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
T1333
The Spectrum Collection
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
311.13
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
1
cLogP
1.77
TPSA
78.51
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
7.0
QED
0.89
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Insulin
Pathway
Membrane Transporter/Ion Channel
Target
Potassium Channel
ABCC8, KCNJ1, KCNJ10, KCNJ11
Indication
diabetes mellitus
MOA
ATP channel blocker
Therapeutic Class
Hypoglycemic Agents
Solubility
DMSO:42mg/mL
Source data